Doxorubicin-loaded, glutaraldehyde-treated murine erythrocytes, once reinjected into circulation, are rapidly taken up by liver and lungs and behave as an organtargeted, slow delivery system for the encapsulated drug. The antitumor activity ofencapsulated doxorubicin (former generic name, adriamycin) was compared with that of the free drug in a murine hepatic and pulmonary tumor model. This was obtained by intrasplenic i jection of L1210 lymphoma cells followed by splenectomy. Different schedules of treatment of tumor-bearing mice with erythrocyte-encapsulated or free doxorubicin were investigated. The optimal schedule of treatment for free doxorubicin proved to be i.v. bolus administration on the day of splenectomy. Under these conditions, the dose producing 50% inhibition of metastatic growth in the liver, as measured by inhibition of 5-[125'Iiodo-2'-deoxyuridine uptake 9 days after tumor induction, was 6.3 mg/kg for free doxorubicin and 0.48 mg/kg for the encapsulated drug. In these conditions pulmonary tumor development was even more efficiently prevented by encapsulated doxorubicin as compared with the free drug. The values of the therapeutic index (TI), dermed as the ratio between the maximal tolerated dose (LDIo) and the minimal effective dose (EDw, producing 90% inhibition of liver metastatic growth), were 4.2 and 1.8 for encapsulated and free doxorubicin, respectively. Doxorubicin (former generic name, adriamycin), an anthracycline antibiotic active against a wide range of tumors, is a very effective antineoplastic drug; however, its use is primarily limited by its remarkable delayed cardiotoxicity (9). Liver targeting of the drug should optimize antimetastatic effects and reduce cardiotoxicity, thus improving its therapeutic index (TI).
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Previous experiments (3) demonstrated that treatment of murine doxorubicin-loaded RBCs with diluted glutaraldehyde solutions dramatically increases liver uptake of the i.v. injected encapsulated drug (70% of the injected dose). Liver targeting is also accompanied by a reduced cardiac uptake of the RBC-encapsulated doxorubicin.
In this report, we present evidence that encapsulation of doxorubicin within liver-targeted autologous RBCs enhances the antitumor activity of this drug towards hepatic metastases of L1210 lymphoma cells in a murine (B6D2F1) liver metastatic tumor model. The TI, defined as the ratio between the maximal tolerated dose (LD10) and the minimal effective dose (producing 90% inhibition of hepatic tumor growth) was found to be 4.2 for encapsulated doxorubicin and 1.8 for the free drug. The increase in the TI is apparently the result of a shift from heart to liver as the main toxicity target of doxorubicin.
Selective targeting of drugs to tumors is the objective of new strategies for cancer treatment that pursue optimization of antineoplastic effects and reduction of toxicity: conjugation of antineoplastic drugs to tumor-specific monoclonal antibodies (1) and encapsulation of drugs within "targeted" liposomes (2) 
insufficient tumor growth in liver and lungs for a therapeutic effect of targeted doxorubicin to be evaluated in a reasonably short time (10-14 days). The time course of hepatic and pulmonary tumor growth after intrasplenic injection (day 1) of 103 L12,10 cells is shown in Fig. 1. 125IdUrd uptake by liver and lungs increased above controls (splenectomized, non-tumor-bearing animals) only from day 8 following splenectomy. Kidney, brain, or intestine involvement was not detectable (i.e., radioactivity in these organs was not higher than in controls) until death occurred on day 11. At this time, the average (± SD) weight of liver and lungs in tumor-bearing, untreated mice was 3.2 ± 0.3 g and 0.40 + 0.005 g, respectively, as compared to 1.1 ± 0.09 g (liver) and 0.12 ± 0.008 g (lungs) in control animals. Metastases Determination of Plasma GOT, GPT, and CK Activities. Splenectomy per se was found to induce a remarkable increase of plasma CK activity: 2500 ± 248 units/ml (mean ± SD of four animals) 5 days after splenectomy, as compared to 1000 ± 97 units/ml (mean of seven animals) for untreated mice (data not shown). CK values returned to normal limits within 14 days after splenectomy ( Table 2) . As compared to administration of free doxorubicin, injection of an equitoxic dose (LD10) of the encapsulated drug determined a higher increase of GOT and GPT activities, with a tendency to return to normal values 8 days after the end of therapy ( (14) , allowing de- tection of metastatic growth beneath the organ surface.
On these grounds, progression of L1210 growth in liver and lungs of BDF1 mice after intrasplenic injection of 103 cells could be adequately monitored (Fig. 1) . Treatment schedules for tumor growth-inhibition studies were designed in order to concentrate drug administration during the 7-to 8-day lag period between tumor-cell injection and the geometric increase in 125IdUrd uptake in the affected organs.
Antineoplastic efficacy of doxorubicin is known to be schedule-dependent (15, 16) . In fact, bolus administration of free doxorubicin proved to be far more effective for L1210 tumor growth inhibition than continuous daily treatment with the same cumulative dose: thus, 8.4 mg/kg administered on day 1 (splenectomy) produced a 70% and 30% inhibition of tLD1o and LD50 values were derived from log-probit dose-mortality plots.
hepatic and pulmonary 125IdUrd uptake, respectively (Fig.  2) , while 30% and 10o inhibition were observed when the same dose was divided into six equal daily subdoses (data not shown). Accordingly, the antitumor activity of bolus-administered free doxorubicin was compared with that of the bolusadministered, RBC-encapsulated drug. The amount of doxorubicin that inhibited hepatic 125IdUrd uptake by 90% (ED90) was found to be 12.3 mg/kg for the free drug and 1.5 mg/kg for the encapsulated drug (Fig. 2) 
